Search is Powered by Google
Cancer / Oncology News

Teen Cancer Survival On The Rise, But More Work Needed

Main Category: Cancer / Oncology
Article Date: 21 Aug 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The first national report detailing survival for teenagers and young adults with cancer shows that survival rates climbed by around 11 per cent over two decades.

The findings, published in the British Journal of Cancer*, looked at survival across all cancers in people aged 13 to 24 between 1979 and 2001.

Previously, statistical information about cancers in people in this age group has been limited, as patients were treated as either a child or adult. Before now, the importance of classing young people as a separate group was not recognised.

It is now understood that the spectrum of cancers affecting young people is different from children and adults and their physical, social and educational needs are also unique.

This report, funded by Cancer Research UK, will serve as a baseline for monitoring and guiding health policy geared towards developing specialised cancer care for teenagers and young people.

Lead author, Professor Jillian Birch, director of Cancer Research UK's Paediatric and Familial Cancer Research Group at The University of Manchester , said: "We found that survival for teenagers and young people with cancer improved overall from 63 per cent between 1979 and 1984 to 74 per cent between 1996 and 2001, which is great news. But more needs to be done to drive this figure even higher.

"It's important that cancer services are tailored to suit teenagers and young adults, as their needs differ from older adults and children - clinically and psychologically. Research like this is needed to measure how much of an impact this tailored treatment could have."

The researchers analysed five-year survival in more than 30,000 13 to 24 year olds diagnosed with cancer in England between 1979 and 2001, and followed them up to 2003.

The greatest increase in survival rates was seen for leukaemia, which increased by 21 per cent over the 23 years studied. But survival for brain tumours, bone cancers and soft tissue sarcomas hasn't changed significantly since the mid-1980s.

Professor Birch added: "Our research has also identified cancers where survival rates remain poor, highlighting the need for continuing research in those areas to drive up survival."

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: "Research like this is vital if we are to measure the impact of changes to the way teenagers with cancer are treated. Recruiting more young people onto clinical trials - which has been a priority for childhood cancer - will help this.

"It's important that this group of patients receive the most appropriate treatment, and Cancer Research UK will continue investing in research to work towards this goal."

Notes

* Survival from cancer in teenagers and young adults in England, 1979 - 2003. Birch et al. British Journal of Cancer. 2008.

CLIC Sargent provided additional funding for this research.

About the British Journal of Cancer (BJC)

The BJC's mission is to encourage communication of the very best cancer research from laboratories and clinics in all countries. Broad coverage, its editorial independence and consistent high standards have made BJC one of the world's premier general cancer journals. The BJC is owned by the charity Cancer Research UK.

About Cancer Research UK

- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
Cancer Research UK




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...